Therapeutic Approach

Archive: October, 2016

Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock

Los Angeles, California, October 26, 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the pricing of an underwritten public offering of 2,127,660 shares of its […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Los Angeles, California, October 2016 – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced that it intends to offer for sale shares of its common stock in […]

Leave Your Comments »

Ritter Pharmaceuticals Concludes Last Patient Visit of its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance

LOS ANGELES (October 17, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed dosing and all monitoring visits in its Phase 2b/3 clinical trial of RP-G28 for […]

Leave Your Comments »

Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum

LOS ANGELES (October 5, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, presented at the 4th Microbiome R&D Business Collaboration Forum & Panel on […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD